Navigation Links
CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells

MADISON, Wis., Aug. 14, 2012 /PRNewswire/ -- CeeTox and Cellular Dynamics International (CDI) today announced the introduction of a new, highly predictive cardiac safety screening service that utilizes human induced pluripotent stem (iPS) cell-derived cardiomyocytes.  The Cardiac Arrhythmia Assessment Screen (CAAS) combines CeeTox's expertise with in vitro toxicity screening and CDI's iCell® Cardiomyocytes to provide a comprehensive profile of drug-induced cardiac toxicity early in the drug development cycle.

Cardiotoxicity is the leading cause for late-stage drug attrition and market withdrawal, and the FDA mandates cardiotoxic safety data on drug candidates prior to entering clinical development. Currently used animal models, non-cardiac cell lines transformed to mimic heart cells, and cadaveric cells do not truly recapitulate human response and are therefore more likely to miss adverse side effects. CDI's iCell Cardiomyocytes are highly pure, fully functional human cardiac cells derived from induced pluripotent stem cells (iPSCs).  They are manufactured in reproducibly high quality and quantity to provide a more reliable, relevant and predictive in vitro model.

CeeTox's CAAS provides a fast, real-time assessment of drug-induced cardiac arrhythmias and biochemical cytotoxicity, thus enabling researchers to monitor both acute and longer-term effects, in contrast to the single time point results obtained with other assays.

Dr. James McKim, Chief Scientific Officer and CeeTox founder, said, "CeeTox's CAAS is an affordable addition to cardiac safety screening panels done during lead optimization, prior to candidate selection. More sensitive, predictable in vitro screens such as this that have direct implications for hazard identification and risk assessment can save drug developers valuable time and money."

"Increasingly researchers are publishing on the more predictive power of our iCell products in safety testing and discovery, and we're working closely with a number of pharma companies to develop assays that will become part of their standard screening platforms," said Chris Parker, Chief Commercial Office. "We're gratified to work with CeeTox as the first CRO to incorporate human iPSC-derived tissue cells as a standard human in vitro model into their screening services, thus reducing the use of animals in testing and providing a more predictive model of in vivo human response."

About CeeTox, Inc.

CeeTox, Inc. was founded in July of 2003 as a Contract Research Organization focused on in vitro toxicity screening of potential drug candidates and chemicals. CeeTox resides in 4,200-square-feet of state-of-the-art laboratory space in the Southwest Michigan Innovation Center (SMIC) (Kalamazoo, MI), a $13 million facility that serves as an incubator for new biotech companies in the Southwest Michigan area. The scientists at CeeTox have a collective experience of more than 100 years in areas of cell culture, biochemistry, and toxicology. The team has analyzed more than 4,000 new chemical entities and has repeatedly demonstrated the value of early in vitro toxicity data in the drug discovery process. See

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See

SOURCE Cellular Dynamics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
2. Cellular Dynamics Launches MyCell™ Services
3. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
4. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
5. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
6. Sanofi US Launches Collaborate Activate Innovation Challenge
7. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
8. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
9. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
10. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
11. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
Post Your Comments:
(Date:10/12/2015)... Elbit Imaging Ltd. ("EI" or the ... board of directors approved a program to repurchase up to ... H Notes and Series I Notes, which are traded on ... the Company will have a significant preference to the purchase ... to time in the open market on the Tel Aviv ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
(Date:10/12/2015)... , October 12, 2015 ... interest from pharmaceutical companies as they look to ... others appear in a new report by  visiongain ... market gains much interest from pharmaceutical companies as ... finding and many others appear in a new ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... In an ongoing effort to provide the ... Texas, child development and pediatric therapy center, is working with TRICARE to emphasize ... options for receiving this kind of care for affected children. Because of concerns ...
(Date:10/13/2015)... ... October 13, 2015 , ... Bambeco, Inc., the premier brand ... announced it closed on a $20.5 million funding round led by ABS Capital ... the Company’s continued rapid growth and expansion, broaden the Company’s product offerings, and ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... show this coming October in Toronto, an exhibition featuring the newest products and ... from, Curly Hair Solutions® couldn’t be more excited to unveil their recent partnership ...
(Date:10/13/2015)... ... October 13, 2015 , ... This ... commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a significant women's health ... Vancouver, BC, Canada. , In a presentation entitled: "The Microbiome and ...
Breaking Medicine News(10 mins):